RxDoctor Payments Data

Javier Torres

Internal Medicine · Mayaguez, PRNPI 1063935039

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.0% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 27.1% of the total. 2025 is the largest year on record at $3,173, more than ten times the $165 reported in 2020. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,107in general payments, 2019–2025

Across 223 payments — averaging $45.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Boehringer Ingelheim$1K
  • United Therapeutics Corporation$1K
  • Bayer$679
  • Boston Scientific$600
  • Johnson & Johnson$509
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$9,80697%
  • Education$3013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,107 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate11$143,173
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,314
Albuterol Sulfate HfaAlbuterol Sulfate14$599
Montelukast Sodium14$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$1,186$143,17311 claims
GSKTrelegy Ellipta$381$7,31411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →